One Year Later: Global Impact of COVID-19 on Nuclear Medicine Departments; an International Follow-up Survey

Francesco Giammarile (f.giammarile@iaea.org)
International Atomic Energy Agency https://orcid.org/0000-0002-0550-7893

Roberto C. Delgado Bolton
University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR)

Noura El Haj
International Atomic Energy Agency

Lutz S. Freudenberg
ZRN Rheinland and ZRN MVZ GmbH

Ken Herrmann
University Hospital Essen

Miriam Mikhail
International Atomic Energy Agency

Olga Morozova
International Atomic Energy Agency

Pilar Orellana
International Atomic Energy Agency

Olivier Pellet
International Atomic Energy Agency

Enrique Estrada L.
International Atomic Energy Agency

Sobhan Vinjamuri
Liverpool University Hospitals

Gopinath Gnanasegaran
Royal Free London

Yaroslav Pynda
International Atomic Energy Agency

Maria C. Navarro M.
International Atomic Energy Agency

Partha Choudhary
Rajiv Gandhi Cancer Institute

Diana Paez
Research Article

Keywords: COVID-19, nuclear medicine, global impact, survey

DOI: https://doi.org/10.21203/rs.3.rs-459551/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Aim:** As a follow-up to the international survey conducted in April 2020, this survey aims to provide a situational snapshot of the COVID-19 impact on nuclear medicine services worldwide, one year later. The survey was designed to determine the impact of the pandemic at two specific time-points: June and October 2020 and compare them to the previously collected data.

**Materials and Methods:** A web-based questionnaire, in the same format as the April 2020 survey was disseminated to nuclear medicine facilities worldwide. Survey data was collected using a secure software platform hosted by the International Atomic Energy Agency (IAEA); it was made available for 6 weeks, from November 23 to December 31, 2020.

**Results:** From 505 replies from 96 countries, data was extracted from 355 questionnaires (of which 338 were fully completed). The responses came from centres evenly distributed in different regions of the world and with different income status. Regional differences and challenges across the world were identified and analysed. Globally, the volume of nuclear medicine procedures decreased by 73.3% in June 2020 and 56.9% in October 2020. Among the nuclear medicine procedures, oncological PET studies showed less of a decline in utilization compared to conventional nuclear medicine and particularly nuclear cardiology. The impact was also significantly less in high-income countries. A trend towards a return to the pre-COVID-19 situation of the supply chains of radioisotopes, generators, and other essential materials was evident.

**Conclusion:** The impact of the COVID-19 pandemic was associated with a significant reduction in nuclear medicine diagnostic and therapeutic procedures throughout 2020. In June, the global decline recorded in the survey was greater than in October when there was a slight improvement. However, the total number of procedures continued below that recorded in April 2020, and less than half of the volumes normally carried out before the pandemic.

Introduction

In December 2019, a new type of coronavirus, 2019-nCoV/SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was extracted and identified from samples of the lower respiratory tract of patients with atypical pneumonia in Wuhan, China (1–6). People with COVID-19 exhibited a wide range of symptoms, ranging from mild ones including fever, fatigue, dry cough, and headache to serious illness with pneumonia, respiratory distress, multiple organ failure, thrombotic accidents, and death. COVID-19, was declared a pandemic by the World Health Organization (WHO) on 11 March 2020 and has since presented the world with unparalleled medical, scientific, social, economic, and ethical challenges.

At the time of writing this paper (April 2021), the COVID-19 pandemic is in a phase of transition, with countries in different phases of recovery and some countries experiencing additional peaks. The WHO dashboard indicates over 140 million confirmed cases of COVID-19, including over 3 million deaths (7).
Several countries have begun rolling out targeted vaccination efforts and new COVID variants have been identified (1–3, 7).

This unprecedented health and social crisis has demonstrated that the preparedness of healthcare systems varies greatly in countries around the world. To mitigate the impact of the COVID-19 crisis on essential health services, the WHO published “COVID-19: Operational Guidance for maintaining essential health services during an outbreak” (8) and the International Atomic Energy Agency (IAEA) produced technical guidance to help nuclear medicine departments continue their services and provided health professionals worldwide with related training and resources, including webinars and open-access publications (9–12). Moreover, in September 2020, the results of a survey on the impact of COVID-19 on nuclear medicine services was published, showing that academic, hospital-based, private, public, inpatient and outpatient facilities, as well as diagnostic and therapeutic services, had been dramatically impacted by the pandemic (13). Regional differences and challenges in the practice of diagnostic or therapeutic nuclear medicine as well as the availability of medical and financial resources were identified.

In this paper, we present the results of a global web-based survey, conducted by the IAEA and designed to determine the impact of the pandemic on nuclear medicine services worldwide at two specific time-points: June and October 2020.

The selection of time points for analysis was based on the stage of the pandemic. Although there were differences in the timing of the COVID-19 waves between regions, most countries were in a post-peak phase at the beginning of the summer (June), while in Autumn (October) most were experiencing the second wave of the pandemic (7). In 1999, the WHO established a six-phase classification for pandemics, a classification that was maintained in the 2005 revision (14). In Phase 1, there is no evidence that a virus circulating in animals causes infections in humans. In Phase 2, a virus circulating in domestic or wild animals is known to have caused infection in humans and is therefore considered a potential pandemic threat. In Phase 3, the virus has caused sporadic cases or small clusters of human cases but has not caused enough person-to-person transmission to sustain community outbreaks. In phase 4, there is person-to-person transmission and community outbreaks can occur, indicating a significantly increased risk to become a pandemic. Phase 5 is characterized by the spread of the virus from person-to-person in at least two countries in one WHO region, the possibility of a pandemic is imminent, and immediate mitigation efforts are required. In phase 6 the community outbreaks are presented in countries of two WHO regions; designation of this phase indicates that a global pandemic is occurring. During the post-peak period, disease levels in most countries with adequate surveillance will have fallen below the maximum levels observed. The period after the peak means that pandemic activity appears to be declining; however, it is not known if there will be new waves. In the post-pandemic period, the disease will have returned to normally observed levels, at this stage it is important to maintain vigilance.

Materials And Methods
As a follow-up of the survey conducted spanning April—May 2020 and published in the *Journal of Nuclear Medicine* in September 2020 (13), an invitation to participate in a web-based questionnaire was extended to nuclear medicine facilities worldwide. Survey entries were collected using a secure software platform hosted by the IAEA, the International Research Integration System (IRIS, https://iris.iaea.org). Invitations to participate in the survey were distributed by the IAEA and through personal and social media networks. The survey was made available for 6 weeks, from November 23 to December 31, 2020.

Questionnaires addressed the following categories: operational aspects of nuclear medicine facilities, impact on diagnostic and therapeutic nuclear medicine procedures, availability of personal protective equipment (PPE), and supply of radiotracers and other essential materials.

All entries were reviewed and checked for missing data, implausible-appearing data, and duplicate or inconsistent entries from the same institution. Data was compiled in Excel for Microsoft 365 (Microsoft, Redmond, Washington). Maps were created using mapbox. Responses to open-ended questions were collected separately.

Where applicable, we report mean and median results (as well as ranges where necessary). Results presented herein are aligned with the aforementioned categories.

**Results**

**1. General**

A total of 505 responses were received from 96 countries of which 338 questionnaires were completed in their entirety; of the remaining 167 entries, which were not fully completed, 17 presented useful data. In total, data included in 355 questionnaires were analysed (Fig. 1).

Globally, the volume of nuclear medicine procedures (diagnostic and therapeutic) decreased by 73.3% in June 2020 and 56.9% in October 2020, compared to the average number of procedures performed before the COVID-19 pandemic. When analysing by procedure, the reductions affected conventional nuclear medicine by 73.9% and 57.5% in June and October respectively, PET by 65.6% and 40.3% and radionuclide therapies by 69.0% and 48.2%. Overall, the results of this survey showed a greater decline in all the nuclear medicine procedures when compared to the data reported by the IAEA in a survey conducted in April 2020 (13) (Fig. 2).

**2. Distribution**

For the analysis, data from participating countries were divided into four geographic regions: Africa, Asia and the Pacific, Europe and Latin America and the Caribbean, using the regional definitions of the IAEA’s Technical Cooperation Programme (11) and by income status as defined by the World Bank (15). Of the 355 institutions included in the analysis, 11.5% came from Africa, 31.8% from the Americas, 38.8% from Asia-Pacific and 17.8% from Europe and when divided by income 2.0% were from low-income countries
(LICs), 22.9% from lower-middle-income countries (LMICs), 37.5% from upper-middle-income countries (UMICs) and 37.7% from high-income countries (HICs) (Fig. 3).

3. Respondents

Seventy-one percent of the respondents were nuclear medicine physicians, 9% were nuclear medicine technologists, 7% medical physicists, 5% radiologists and 8% others (mainly radiopharmacists). Forty-four percent of the participants worked in community hospitals, 36% were university-based employees, and 20% worked in private practice.

Only 18% of respondents to this second survey (October 2020) had also participated in the first (April 2020).

4. Impact on Nuclear Medicine Diagnostic Procedures

4.1. Share of Outpatients

On average, 70% (median, 80%) of all services provided by participating centres are for outpatients. Tables 1 show variability in the proportion of outpatients visits in a centre-based analysis.

**Table 1a:** Variability in the proportion of outpatients visits in a centre-based analysis per region in percentages of the total 355 responses.

| Regions                      | June (%) | October (%) |
|------------------------------|----------|-------------|
|                              | -        | + | = | ? | - | + | = | ? |
| Africa                       | 8.9      | 0.3 | 1.1 | 1.1 | 5.0 | 3.1 | 2.3 | 1.1 |
| North America                | 5.6      | 0.3 | 2.3 | 0.3 | 3.9 | 1.9 | 2.3 | 0.3 |
| Latin America and the Caribbean | 17.7   | 2.2 | 2.8 | 0.5 | 13.2 | 4.2 | 5.3 | 0.5 |
| Far East                     | 7.0      | 0.9 | 2.8 | 0.9 | 5.3 | 1.1 | 4.2 | 0.9 |
| Middle East and South Asia   | 13.2     | 1.4 | 1.7 | 0.5 | 8.7 | 3.1 | 4.2 | 0.9 |
| South East Asia and the Pacific | 7.9     | 0.9 | 1.7 | 0.0 | 5.9 | 1.1 | 3.4 | 0.0 |
| Eastern Europe               | 5.0      | 1.1 | 1.4 | 0.3 | 4.2 | 1.1 | 2.3 | 0.3 |
| Western Europe               | 4.2      | 1.4 | 3.7 | 0.5 | 2.5 | 1.8 | 5.0 | 0.5 |
| Total                        | 66.9     | 8.5 | 17.5 | 4.1 | 49.0 | 17.5 | 29.0 | 4.5 |

**Table 1b:** Variation per income groups in percentage of the 355 total answers
4.2. Conventional Nuclear Medicine Procedures

Of the responding centres, 301 perform conventional nuclear medicine diagnostic procedures of which 1% occur in LICs, 23% in LMICs, 36.5% in UMICs and 39.5% in HICs.

Compared to a pre-COVID-19 baseline, the utilization of conventional nuclear medicine diagnostic procedures changed dramatically in June and October 2020. Globally, decreases were more evident in June (73.9%) rather than October (57.5%) 2020. The greatest impact was seen in the Americas in June, and in the Eastern European countries in October, while Western European countries were less affected. Similarly, the impact was more evident in LMICs than in HICs. Regarding the type of studies, the major decreases were observed in myocardial perfusion imaging in June and in bone scans in October (Fig. 4).

### 4.3. PET/CT Procedures

The responding centres performing PET procedures were 182; 0% in LICs, 16% in LMICs, 40% in UMICs and 44% in HICs.

Compared to activity pre-COVID-19, PET/CT procedures decreased in June (65.6%) and October 2020 (40.3%). Decreases affected mainly Latin America and South East Asian countries in June for all PET procedures. In October, the situation showed global recovery. As with conventional nuclear medicine activity, the impact was more evident in LMICs both in June and in October, with persistent differences during the recovery phase. For oncological PET studies, in June the decrease in HICs was 53.5% versus 15% in October. In LMICs, the decrease was 89% in June and 46.7% in October. Non-oncologic studies were affected slightly more than oncologic studies. Gallium activity dramatically decreased in Latin America (93.8% in June) and Asia, while North America and Western Europe were less affected (Fig. 5).

### 5. Impact on Radionuclide Therapies

The responding centres performing radionuclide therapies were 301; 1% in LICs, 23% in LMICs, 36.5% in UMICs and 39.5% in HICs.
Compared to activity pre-COVID-19, radionuclide therapies changed dramatically in June (69.0%) and October (48.2%) 2020. Decreases affected LMICs more significantly than other regions, mainly in June (Fig. 6).

6. Personal Protective Equipment (PPE)

Thirty-five percent of the respondents reported a shortage of PPE in June 2020. This percentage dropped to 25% in October 2020. As for the availability of PPE, 32% of sites reported that stockpiles of PPE would last for more than one month while fewer than 2 days for only 7%.

Figure 7 show variability in the shortage of PPE. Decreases affected mainly the Latin American region and LMICs.

7. Employee Health and Organizational Changes

Sixty percent of respondents experienced COVID-19 infections within their own departments: 40% reported that less than 20% of staff were infected, whereas 14% reported infection rates between 20 and 40%, and 6% observed rates exceeding 40%.

Thirty-one percent of the respondents experienced a relocation of their employees, and in 3% of the cases, the number of relocated employees exceeded 40%. However, in most cases the relocated employees returned to the nuclear medicine service in October 2020.

More than the half of respondents modified working hours; in 16% of the cases for less than 20% of their staff (short, part-time, or turnover), 22% modified their work schedule between 20% and 70%, and 14% modified working hours by more than 70%. In approximately 20% of the cases, the employees were laid-off (Fig. 8).

8. Demand and Supplies of Materials

8.1. Demand

Approximately half of the respondents modified orders of 99mTc generators; of these, 11% maintained their orders for more than 70% of their regular demand, 22% maintained between 20% and 70% of their orders, and 8% maintained less than 20% of their orders. Another 7% cancelled their generator orders entirely.

8.2. Supply

Insufficient supplies of radioisotopes, generators, and kits were reported especially for 131I and 99mTc generators. The reduction of essential supplies varied significantly between regions and was more frequently reported from Africa, Asia, Oceania, and Latin America (Fig. 9).

Discussion
The coronavirus disease 2019 (COVID-19) pandemic has presented health-care systems worldwide with significant challenges. The majority of countries have experienced a lockdown and a shift in allocation of healthcare resources to cope with the increased burden of COVID-19 cases. In many regions the healthcare systems have been stressed to their limits, having to reduce non urgent procedures and concentrate all available resources to attend to COVID-19 patients. In doing so, the global provision of in- and outpatient services for other diseases have been compromised to varying degrees, including by the necessity to implement additional infection prevention and control measures (16–18).

The impact of the pandemic on nuclear medicine departments and their services worldwide was recently assessed by a survey conducted by the IAEA (13). It showed a global decrease in procedures performed in April 2020: studies done with 99mTc decreased by 54%; PET studies decreased by 36% and radionuclide therapies by 45% on average. The main reasons for this decline were attributed to the postponement of non-emergent procedures and to the disruption in the supply chain, mainly affecting LMICs.

Today, the pandemic and the associated lockdown have redesigned the usual risk/benefit ratio which compares the infection exposure risk (for the patient and for staff) vs. the risk associated with delaying or cancelling nuclear medicine procedures. As we enter another phase of the pandemic, plans have been initiated to restore the provision of deferred services.

According to the IAEA medical imaging and nuclear medicine global resources database – IMAGINE (19) there are approximately 27,000 SPECT scanners available worldwide, of which, less than 0.1% are installed in LICs, 3% in LMICs, 16.5% in UMICs and 20.3% in HICs. Regarding PET scanners, there are approximately 5,700 scanners available, of which less than 0.1% are installed in LICs, around 8% in LMICs, 15% in UMICs and 77% in HICs (19).

The aim of this new IAEA online survey was to measure the impact of COVID-19 on nuclear medicine departments at two fixed times in 2020, namely June and October. The selection of temporal baselines for analysis was based on the stage of the pandemic. In June, most countries were in a post-peak phase, while in October most were experiencing a new wave.

It was noted that the decline of nuclear medicine procedures in June was greater that in October, and higher than what was reported in the survey conducted in April 2020 (13), at the beginning of the pandemic, and still far from returning to average numbers of procedures before COVID-19.

Although, the results of this follow-up survey cannot be directly compared with the previous one (13), given than few of the responses (less than 20%) came from the previous respondents. However, it allows to have an overview of the global impact of COVID-19 on the practice of nuclear medicine.

The reason for this lower response rate could be attributed to the lower motivation of potential respondents to repeat the survey and to the great number of surveys and virtual event that have been deployed during the pandemic. Thus, only June and October 2020 are compared herein. Recovery phases are not discussed as regions differed in this regard.
A total of 505 centres from 96 countries responded to the questionnaire. However, after removal of duplicates and insufficient replies, available data could be extracted from 355 questionnaires. The received responses came from institutions uniformly distributed across the world and according to income status. This highly balanced distribution among participating centres was not obtained in our previous survey, where the responses from high-income countries were preponderant (13).

Globally, the volume of nuclear medicine procedures (diagnostic and therapeutic) decreased by 73.3% in June 2020 and 56.9% in October 2020, compared to the average number of procedures performed before the COVID-19 pandemic, varying markedly between regions and countries, with the greatest regional decreases in Latin America. Significant reductions affected about 80% and 60% of conventional diagnostic procedures, 65% and 40% of PET, and 70% and 50% of therapeutic procedures in June and October, respectively. The biggest impact was seen in low- to low-middle income countries, both in June and October (despite the partial recovery), while high-income countries exhibited greater continuity of nuclear medicine services since the outset of the pandemic. This observation was also seen in a recent national survey in examining the impact of COVID-19 on Nuclear Medicine services in 2020 compared to 2019 (20). The initial significant reduction in nuclear medicine procedures in the first three weeks of the COVID-19 pandemic did not continue, but there was no compensation of the previously not performed services (21). The decrease in diagnostics and therapy procedures of benign diseases was particularly severe (20).

Similar to the interpretation of the April 2020 survey, this decrease could be attributed to several factors such as changes in scheduling workflow with reduction in the number of appointments, reluctance of patients to visit a medical centre due to safety concerns, deferral of non-urgent studies, deferral of surgeries and pre- or perioperative evaluations, shortages of essential supplies, implementation of infection prevention and control (IPC) measures including social distancing and decreasing the number of health workers at a given time to reduce staff exposure, and increasing the time assigned to each patient to include greater disinfection and cleaning procedures (13).

Also, the decline in diagnostic tests was more pronounced for conventional nuclear medicine studies (thyroid, cardiac, bone, and lung scans) than for PET/CT scans. This may be for two reasons: first, PET tracers are produced through local cyclotrons, whereas most of the countries rely on international flights for the supply of $^{99m}$Tc/$^{99}$Mo generators and other radioisotopes; and second, the more urgent nature of cancer assessments is with PET/CT.

Regarding clinical indications for referral to both conventional nuclear medicine and PET/CT, the greatest reduction in exams was seen for myocardial perfusion and non-oncological studies. This could be attributed to the trepidation of patients fearing exposure to the virus in a healthcare setting and, as above, to certain exams being deemed less urgent, a pragmatic choice in this period of crisis. Compared to the previous survey (13), the global decrease was more pronounced, probably because of the minor impact felt by high-income countries which represented a larger constituent group in the first survey. Specifically, the changes in availability of technetium or gallium generators and of radiopharmaceutical delivery in
general were less detrimental to the continuity of services in high-income countries whereas low- to low-middle income countries experienced greater insufficiencies in supplies of radioisotopes, generators, and kits.

Notably, some centres reported an increase in their activities, namely 6.5% and 13% for conventional nuclear medicine diagnostic procedures, 10.5% and 21% for PET, and 5.5% and 13% for therapeutic procedures in June and October respectively. This aspect, uniformly distributed across the world and according to income status, reflects a trend towards the recovery of previous activity.

As for radionuclide therapies, the main reduction was reported in radioiodine therapies for benign thyroid disease followed by thyroid cancer and radiosynovectomy in June, similar to what was reported in the previous survey (13); and in radiosynovectomy in October. Compared to less affected procedures, such as selective internal radiation therapy, peptide receptor radionuclide therapy, and prostate-specific membrane antigen radioligand therapy, the latter are treatments that could be deferred with less impact on patient prognosis.

Adoption of IPC measures is essential to protect health workers and patients while continuing to provide medical services (10, 11, 22–24). Thus, availability of PPE is critical. In our survey, 35% and 25% of participants, respectively in June and October 2020, reported shortage of PPE, with no significant differences among geographic regions. Regarding the 50% rate reported in the previous survey conducted in April (13), the trend of a general return to normality is evident, due to the increase of supplies. Conversely, COVID-19 infections in staff were reported in 60% of surveyed centres, with a great increase in nosocomial infections compared to 15% reported in April (13).

The overall significant decrease in nuclear medicine procedures also resulted in a reduction of working hours in almost half of the responding centres, affecting large numbers of staff.

The reduction of essential supplies was more frequently reported for Africa, Asia, Oceania, and Latin America. Surveys conducted by international bodies such as the IAEA highlight the need to ensure a uniform and consistent supply of radioisotopes, generators, and kits across the globe and to ensure regional imbalances in service delivery are minimised. This can enable the return to pre-pandemic activity levels and hopefully lay the foundation for greater health system strengthening to meet enhanced demands for patient care, as well as for vital educational, research and developmental activity.

**Conclusion**

Following the situational snapshot of the COVID-19 impact on nuclear medicine services conducted in April 2020 by the same team of investigators, this second survey in October 2020 aimed to provide a follow-up. The current survey, with 505 responding centres, were more uniformly distributed across the world regions and by country income status, constituting a small but more reliable sampling of existing nuclear medicine centres worldwide.
Our data provides a global perspective of the impact of COVID-19 on nuclear medicine services. Among the different nuclear medicine procedures, PET/CT for oncologic indications showed a lesser decrease in utilization rates than did conventional nuclear medicine and particularly nuclear cardiology. As for radionuclide therapies, the main reduction was reported in radioiodine therapies for benign thyroid disease followed by thyroid cancer and radiosynovectomy. High-income countries exhibited greater continuity of nuclear medicine services since the outset of the pandemic compared to lower-resource settings. The survey also showed a trend in the restitution towards normalcy of the supply chains of radioisotopes, generators, and other essential materials. In June, the global decline recorded in the survey was greater than in October when there was a slight improvement. However, the total number of procedures continued below that recorded in April 2020, and less than half of the volumes normally carried out before the pandemic.

**Abbreviations**

COVID-19 = Coronavirus Disease 2019

CNM = Conventional Nuclear Medicine

HIC = High-Income Countries

IAEA = International Atomic Energy Agency

IPC - Infection Prevention and Control

IRIS = International Research Integration System

LIC = Low-Income Countries

LMIC = Lower-Middle-Income Countries

PET = Positron Emission Tomography

PPE = Personal Protective Equipment

UMIC = Upper-Middle-Income Countries

WHO = World Health Organisation

**Declarations**

**Compliance with Ethical Standards**

Disclosure of potential conflicts of interest

Funding: no funding was involved
Research involving human participants and/or animals

Conflict of Interest:

Francesco Giammarile declares that he has no conflict of interest.

Roberto C. Delgado Bolton declares that he has no conflict of interest.

Noura El-Haj declares that she has no conflict of interest.

Lutz S. Freudenberg declares that he has no conflict of interest.

Ken Herrmann declares that he has no conflict of interest.

Miriam Mikhail declares that she has no conflict of interest.

Olga Morozova declares that she has no conflict of interest.

Pilar Orellana declares that she has no conflict of interest.

Olivier Pellet declares that he has no conflict of interest.

Enrique Estrada L. declares that he has no conflict of interest.

Sobhan Vinjamuri declares that he has no conflict of interest.

Gopinath Gnanasegaran declares that he has no conflict of interest.

Yaroslav Pynda declares that he has no conflict of interest.

Maria C. Navarro M. declares that she has no conflict of interest.

Partha S. Choudhury declares that he has no conflict of interest.

Diana Paez declares that she has no conflict of interest.

Informed consent

Informed consent: this survey on nuclear medicine activities do not implies directly patient participation.

Ethical approval: This article does not contain any studies with human participants performed by any of the authors

References

1. Park SE. Epidemiology, virology, and clinical features of severe acute respiratory syndrome - coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19). Clin Exp Pediatr. 2020;63(4):119-24.
2. Czernin J. Dr. Li Wenliang and the Time of COVID-19. J Nucl Med. 2020;61(5):625.
3. Li X, Cui W, Zhang F. Who Was the First Doctor to Report the COVID-19 Outbreak in Wuhan, China? J Nucl Med. 2020;61(6):782-3.
4. Treglia G, Pascale M, Lazzeri E, van der Bruggen W, Delgado Bolton RC, Glaudemans A. Diagnostic performance of (18)F-FDG PET/CT in patients with spinal infection: a systematic review and a bivariate meta-analysis. Eur J Nucl Med Mol Imaging. 2020;47(5):1287-301.
5. Delgado Bolton RC, Calapaqui Teran AK, Erba PA, Giammarile F. Medical imaging in times of pandemic: focus on the cornerstones of successful imaging. Eur J Nucl Med Mol Imaging. 2021.
6. Cabrera Villegas A, Romero Robles LG, Boulvard Chollet XLE, Albornoz Almada MC, Mangas Losada M, Garrastachu P, et al. [(18)F]-FDG PET/CT in oncologic patients with unsuspected asymptomatic infection with SARS-CoV-2. Eur J Nucl Med Mol Imaging. 2020.
7. WHO. Coronavirus Disease (COVID-19) Dashboard 2021 [updated 26-02-2021. Available from: https://covid19.who.int/.
8. WHO. Coronavirus disease (COVID-19) technical guidance: maintaining Essential Health Services and Systems. 2019 [Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/maintaining-essential-health-services-and-systems.
9. Paez D, Gnanasegaran G, Fanti S, Bomanji J, Hacker M, Sathekge M, et al. COVID-19 pandemic: guidance for nuclear medicine departments. Eur J Nucl Med Mol Imaging. 2020;47(7):1615-9.
10. Huang HL, Gnanasegaran G, Paez D, Fanti S, Hacker M, Sathekge M, et al. Nuclear medicine services after COVID-19: gearing up back to normality. Eur J Nucl Med Mol Imaging. 2020;47(9):2048-53.
11. IAEA. COVID-19 Pandemic: Technical Guidance for Nuclear Medicine Departments 2020 [Available from: https://www-pub.iaea.org/MTCD/Publications/PDF/COVID19_web.pdf
12. IAEA. Human Health Campus Webinars 2020 [Available from: https://humanhealth.iaea.org/HHW/covid19/webinars.html
13. Freudenberg LS, Paez D, Giammarile F, Cerchi J, Modiselle M, Pascual TNB, et al. Global Impact of COVID-19 on Nuclear Medicine Departments: An International Survey in April 2020. J Nucl Med. 2020;61(9):1278-83.
14. WHO. About pandemic phases 1999 [Available from: https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/data-and-statistics/pandemic-influenza/about-pandemic-phases.
15. Bank W. World Bank Data 2021 [updated 26-02-2021. Available from: https://data.worldbank.org/indicator/Published2020.
16. Kayastha SR, Parajuli B, Basi A, Shrestha D. Orthopaedic Services during Nationwide COVID-19 Lockdown: Dhulikhel Hospital, Kathmandu University Hospital Experience and Review of Literature. Kathmandu Univ Med J (KUMJ). 2020;18(70):29-35.
17. Einstein AJ, Shaw LJ, Hirschfeld C, Williams MC, Villines TC, Better N, et al. International Impact of COVID-19 on the Diagnosis of Heart Disease. J Am Coll Cardiol. 2021;77(2):173-85.
18. Tagliafico AS, Albano D, Torri L, Messina C, Gitto S, Bruno F, et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on radiology research: An Italian survey. Clin Imaging. 2021;76:144-8.

19. IAEA. IMAGINE - IAEA medical imaging and nuclear medicine global resources database 2021 [Available from: https://humanhealth.iaea.org/HHW/DBStatistics/IMAGINE.html.

20. Freudenberg LS, Essler M, Herrmann K. [Impact of COVID-19 on Nuclear Medicine Procedures in Germany 2020 - Results of a National Survey]. Nuklearmedizin. 2021.

21. Freudenberg LS, Dittmer U, Herrmann K. Impact of COVID-19 on Nuclear Medicine in Germany, Austria and Switzerland: An International Survey in April 2020. Nuklearmedizin. 2020;59(4):294-9.

22. Gnanasegaran G, Paez D, Sathekge M, Giammarile F, Fanti S, Chiti A, et al. Coronavirus (COVID-19) pandemic mediated changing trends in nuclear medicine education and training: time to change and scintillate. Eur J Nucl Med Mol Imaging. 2021.

23. Huang HL, Gnanasegaran G, Paez D, Fanti S, Hacker M, Sathekge M, et al. Correction to: Nuclear medicine services after COVID-19: gearing up back to normality. Eur J Nucl Med Mol Imaging. 2020;47(9):2220.

24. Skali H, Murthy VL, Paez D, Choi EM, Keng FYJ, Iain MA, et al. Guidance and best practices for reestablishment of non-emergent care in nuclear cardiology laboratories during the coronavirus disease 2019 (COVID-19) pandemic: An information statement from ASNC, IAEA, and SNMMI : Endorsed by the Infectious Diseases Society of America. J Nucl Cardiol. 2020;27(5):1855-62.

**Figures**

![Survey Flowchart](image-url)
Figure 1
Flow diagram of survey completion

Figure 2
Decrease in nuclear medicine procedures in April (13), June and October 2020
Figure 3

Geographic and economic distribution of the 355 participating centres Note: The designations employed and the presentation of the material on this map do not imply the expression of any opinion whatsoever on the part of Research Square concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. This map has been provided by the authors.
Figure 4

Average variation in conventional nuclear medicine diagnostic procedures by country in June and October 2020 Note: The designations employed and the presentation of the material on this map do not imply the expression of any opinion whatsoever on the part of Research Square concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. This map has been provided by the authors.
Figure 5

Average variation in PET diagnostic procedures by country in June and October 2020 Note: The designations employed and the presentation of the material on this map do not imply the expression of any opinion whatsoever on the part of Research Square concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. This map has been provided by the authors.
**Figure 6**

Average variation in therapeutic procedures by country in June and October 2020 Note: The designations employed and the presentation of the material on this map do not imply the expression of any opinion whatsoever on the part of Research Square concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. This map has been provided by the authors.
Figure 7

Average variation in the shortage of PPE by country in June and October 2020 Note: The designations employed and the presentation of the material on this map do not imply the expression of any opinion whatsoever on the part of Research Square concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. This map has been provided by the authors.
Figure 8

Employment status Note: The designations employed and the presentation of the material on this map do not imply the expression of any opinion whatsoever on the part of Research Square concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. This map has been provided by the authors.
**Figure 9**

Percentage of the responses indicating sufficient (yes) or insufficient (no) supply of materials in June and in October 2020 ('not applicable' answers are not indicated).

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- additionalmaterial.docx